SEPARATION OF ALPHA-ADRENERGIC AND IMIDAZOLINE/GUANIDINIUM RECEPTIVE SITES (IGRS) ACTIVITY IN A SERIES OF IMIDAZOLINE ANALOGS OF CIRAZOLINE

被引:12
作者
BRASILI, L
PIGINI, M
MARUCCI, G
QUAGLIA, W
MALMUSI, L
LANIER, SM
LANIER, B
机构
[1] UNIV MODENA,DIPARTIMENTO SCI FARMACEUT,I-41100 MODENA,ITALY
[2] UNIV CAMERINO,DIPARTIMENTO SCI CHIM,I-62032 CAMERINO,ITALY
[3] MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425
关键词
D O I
10.1016/0968-0896(95)00132-Z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To characterize the structure-activity relationship between alpha(1)-adrenergic receptors and the family of imidazoline/guanidinium receptive sites (IGRS), we synthesized and characterized a series of analogues of cirazoline, an imidazoline with high affinity for alpha(1)-adrenergic receptors and IGRS. Analysis of potency, affinity and efficacy of the synthesized molecules indicate different structure-activity relationships for IGRS and alpha-adrenergic receptors. Cirazoline exhibits a 25-fold higher affinity for IGRS (pK(i) 7.9) than for alpha(1)-adrenergic receptors. Replacement of the cyclopropyl ring with an isopropoxy group resulted in a molecule that was 20-fold more selective for alpha(1)-adrenergic receptors than for IGRS, i.e. a 500-fold increase in selectivity relative to cirazoline. The unsubstituted derivative 3 and the methyl and allyl substituted analogues 4 and 12 are of particular interest: compounds 3 and 4 recognize IGRS with high affinity (pK(i) 7.83 and 8.17) and high selectivity (398 and 123) with respect to the alpha(1)-adrenergic receptor; compound 12 also recognizes IGRS with high affinity (pK(i) 8.08) and high selectivity (228 and 138) with respect to the alpha(2B), and alpha 2(C)-adrenergic receptor subtypes. Thanks to their IGRS selectivity, these compounds represent novel and valuable pharmacological tools for the characterization and elucidation of the physiological role of these novel sites.
引用
收藏
页码:1503 / 1509
页数:7
相关论文
共 30 条
[1]  
BAGAN H, Patent No. 6800850
[2]  
BARTUNEN F, 1992, FUNDMAN CLIN PHARM, V6, P57
[3]  
BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232
[4]  
CARPENE C, 1994, 2 INT S IM REC NEW Y, pS29
[5]  
CHAPLEO CB, 1981, BRIT J PHARMACOL, V74, pP842
[6]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[7]   ARYLOXYACETAMIDINES AND 2-(ARYLOXYMETHYL)-IMIDAZOLINES [J].
DJERASSI, C ;
SCHOLZ, CR .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1947, 69 (07) :1688-1692
[8]  
DUZIC E, 1992, J BIOL CHEM, V267, P9844
[9]   COMPARISON OF DISSOCIATION CONSTANTS AND OF RELATIVE EFFICACIES OF SELECTED AGONISTS ACTING ON PARASYMPATHETIC RECEPTORS [J].
FURCHGOTT, RF ;
BURSZTYN, P .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1967, 144 (A2) :882-+
[10]   THE EFFECTS OF IDAZOXAN AND OTHER ALPHA-2-ADRENOCEPTOR ANTAGONISTS ON FOOD AND WATER-INTAKE IN THE RAT [J].
JACKSON, HC ;
GRIFFIN, IJ ;
NUTT, DJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (01) :258-262